Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Cyclin E overexpression sensitizes triple negative breast cancer to Wee1 kinase Inhibition.

Chen X, Low KH, Alexander A, Jiang Y, Karakas C, Hess KR, Carey JP, Bui T, Vijayaraghavan S, Evans KW, Yi M, Ellis DC, Cheung KL, Ellis IO, Fu S, Meric-Bernstam F, Hunt KK, Keyomarsi K.

Clin Cancer Res. 2018 Sep 4. pii: clincanres.1446.2018. doi: 10.1158/1078-0432.CCR-18-1446. [Epub ahead of print]

PMID:
30181387
2.

A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.

Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F.

Clin Cancer Res. 2017 Nov 1;23(21):6468-6477. doi: 10.1158/1078-0432.CCR-17-0615.

PMID:
29093017
3.

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.

Arango NP, Yuca E, Zhao M, Evans KW, Scott S, Kim C, Gonzalez-Angulo AM, Janku F, Ueno NT, Tripathy D, Akcakanat A, Naing A, Meric-Bernstam F.

Breast Cancer Res. 2017 Aug 15;19(1):93. doi: 10.1186/s13058-017-0878-6.

4.

Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapy.

Kim J, de Sampaio PC, Lundy DM, Peng Q, Evans KW, Sugimoto H, Gagea M, Kienast Y, do Amaral NS, Rocha RM, Eikesdal HP, L√łnning PE, Meric-Bernstam F, LeBleu VS.

JCI Insight. 2016 Dec 22;1(21):e90733. doi: 10.1172/jci.insight.90733.

5.

Correction: Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.

McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin A, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F.

PLoS One. 2016 Mar 8;11(3):e0151121. doi: 10.1371/journal.pone.0151121. eCollection 2016. No abstract available.

6.

Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes.

McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, Eterovic AK, Sangai T, Holder AM, Sharma C, Chen H, Do KA, Tarco E, Gagea M, Naff KA, Sahin A, Multani AS, Black DM, Mittendorf EA, Bedrosian I, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F.

PLoS One. 2015 Sep 1;10(9):e0136851. doi: 10.1371/journal.pone.0136851. eCollection 2015. Erratum in: PLoS One. 2016;11(3):e0151121.

7.

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.

Hassan B, Akcakanat A, Sangai T, Evans KW, Adkins F, Eterovic AK, Zhao H, Chen K, Chen H, Do KA, Xie SM, Holder AM, Naing A, Mills GB, Meric-Bernstam F.

Oncotarget. 2014 Sep 30;5(18):8544-57.

8.

Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.

Blanco E, Sangai T, Wu S, Hsiao A, Ruiz-Esparza GU, Gonzalez-Delgado CA, Cara FE, Granados-Principal S, Evans KW, Akcakanat A, Wang Y, Do KA, Meric-Bernstam F, Ferrari M.

Mol Ther. 2014 Jul;22(7):1310-1319. doi: 10.1038/mt.2014.27. Epub 2014 Feb 26.

9.

FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer.

Hollier BG, Tinnirello AA, Werden SJ, Evans KW, Taube JH, Sarkar TR, Sphyris N, Shariati M, Kumar SV, Battula VL, Herschkowitz JI, Guerra R, Chang JT, Miura N, Rosen JM, Mani SA.

Cancer Res. 2013 Mar 15;73(6):1981-92. doi: 10.1158/0008-5472.CAN-12-2962. Epub 2013 Feb 1.

10.

Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells.

Fan F, Samuel S, Evans KW, Lu J, Xia L, Zhou Y, Sceusi E, Tozzi F, Ye XC, Mani SA, Ellis LM.

Cancer Med. 2012 Aug;1(1):5-16. doi: 10.1002/cam4.4. Epub 2012 Jun 8.

11.

Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis.

Battula VL, Shi Y, Evans KW, Wang RY, Spaeth EL, Jacamo RO, Guerra R, Sahin AA, Marini FC, Hortobagyi G, Mani SA, Andreeff M.

J Clin Invest. 2012 Jun;122(6):2066-78. doi: 10.1172/JCI59735. Epub 2012 May 15.

12.

Alternative origins of stroma in normal organs and disease.

Kolonin MG, Evans KW, Mani SA, Gomer RH.

Stem Cell Res. 2012 Mar;8(2):312-23. doi: 10.1016/j.scr.2011.11.005. Epub 2011 Dec 8. Review.

13.

Epithelial-mesenchymal transition and cancer stem cells: a dangerously dynamic duo in breast cancer progression.

May CD, Sphyris N, Evans KW, Werden SJ, Guo W, Mani SA.

Breast Cancer Res. 2011 Feb 8;13(1):202. doi: 10.1186/bcr2789. Review.

14.

Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy.

Mego M, Mani SA, Lee BN, Li C, Evans KW, Cohen EN, Gao H, Jackson SA, Giordano A, Hortobagyi GN, Cristofanilli M, Lucci A, Reuben JM.

Int J Cancer. 2012 Feb 15;130(4):808-16. doi: 10.1002/ijc.26037. Epub 2011 Apr 27.

15.

Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes.

Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, Hartwell K, Onder TT, Gupta PB, Evans KW, Hollier BG, Ram PT, Lander ES, Rosen JM, Weinberg RA, Mani SA.

Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15449-54. doi: 10.1073/pnas.1004900107. Epub 2010 Aug 16. Erratum in: Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):19132.

16.

Epithelial-mesenchymal transition-derived cells exhibit multilineage differentiation potential similar to mesenchymal stem cells.

Battula VL, Evans KW, Hollier BG, Shi Y, Marini FC, Ayyanan A, Wang RY, Brisken C, Guerra R, Andreeff M, Mani SA.

Stem Cells. 2010 Aug;28(8):1435-45. doi: 10.1002/stem.467.

17.

Peroxisome proliferator-activated receptor (PPAR): balance for survival in parasitic infections.

Chan MM, Evans KW, Moore AR, Fong D.

J Biomed Biotechnol. 2010;2010:828951. doi: 10.1155/2010/828951. Epub 2010 Feb 10. Review.

18.

Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine.

Evans KW, Boan JA, Evans JL, Shuaib A.

Pharmacoeconomics. 1997 Nov;12(5):565-77.

PMID:
10174323
19.

Characterization of recombinant E. coli ATCC 11303 (pLOI 297) in the conversion of cellulose and xylose to ethanol.

Padukone N, Evans KW, McMillan JD, Wyman CE.

Appl Microbiol Biotechnol. 1995 Oct;43(5):850-5.

PMID:
7576551
20.

Oral penicillin.

GYORGY P, EVANS KW, et al.

Pa Med J. 1946 Jan;49:409-16. No abstract available.

PMID:
21016491

Supplemental Content

Loading ...
Support Center